About Avalon GloboCare Corp. - Common Stock (ALBT)
Avalon GloboCare Corp. is a healthcare innovation company focused on advanced cell-based technologies and the development of transformative treatment solutions. The firm specializes in the research, design, and commercialization of cell therapies, with a particular emphasis on addressing unmet medical needs in areas such as cancer, immunology, and regenerative medicine. By leveraging its proprietary platforms and strategic partnerships, Avalon aims to drive the next generation of cellular medicine, improving patient outcomes and enhancing the efficacy of therapies. Through its integrated approach, the company is committed to advancing the frontiers of healthcare and making a meaningful impact on global health challenges. Read More
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Avalon GloboCare Corp. (NASDAQ: ALBT) and YOOV Group Holding Limited is fair to Avalon shareholders. Upon closing of the proposed transaction, Avalon shareholders are expected to own between approximately 2.5% to 2.2% of the common stock of the combined company.
The Ademi Firm is investigating Avalon (Nasdaq: ALBT) for possible breaches of fiduciary duty and other violations of law in its transaction with YOOV.
Fusion Fuel Green (Nasdaq: HTOO) announced the appointment of Luisa Ingargiola to its Board of Directors, effective Feb. 24, 2025. Ingargiola will serve as chairperson of the Audit Committee, replacing Rune Magnus Lundetrae, who will remain on the board. She will also join the Nominating, Audit, and Compensation Committees. Ingargiola, currently CFO of Avalon GloboCare Corp. (NASDAQ: ALBT), brings extensive experience in corporate governance and financial oversight. Chairman Jeffrey Schwarz highlighted her expertise in capital markets and strategic growth as key assets for Fusion Fuel’s long-term value creation.
Trump Media & Technology Group (NASDAQ: DJT), the company behind Truth Social, witnessed a sharp surge on Election Day, with shares climbing as traders bet that a second Trump presidency could reignite business prospects. The stock, often regarded as a proxy for the former president’s White House chances, has seen heavy retail interest, especially on platforms like WallStreetBets , where it topped discussions, opening the way to small cap stocks some mentioned herein.
Avalon GloboCare' partner, Laboratory Services MSO, begins manufacturing the GeeWhiz External Condom Catheter, an FDA-registered male incontinence device. Set for a Q3 2024 launch.
